Geographic Atrophy Market Growth, Trends & Forecast 2025 | Top key players - Iveric Bio, Alkeus Pharmaceuticals, Inc., Allegro Ophthalmics, LLC.

The Global Geographic Atrophy (GA) Market reached US$ 18.5 billion in 2022 and is expected to reach US$ 35.1 billion by 2030 growing with a CAGR of 7.2% during the forecast period 2024-2031.

Geographic Atrophy Market report, published by DataM Intelligence, delivers detailed insights and analysis on major market trends, growth prospects, and emerging challenges. With a strong focus on providing actionable intelligence, DataM Intelligence enables businesses to make well-informed decisions and maintain a competitive edge. By blending both qualitative and quantitative research approaches, the company offers thorough reports that support clients in navigating complex market environments, driving strategic expansion, and capitalizing on new opportunities in today's rapidly evolving global landscape.

The Geographic Atrophy Market focuses on treatments for a severe form of age-related macular degeneration (AMD) that leads to vision loss. It involves therapies aimed at slowing or halting the progression of retinal cell damage, improving patients' quality of life. The market is driven by innovations in retinal disease treatments and the growing aging population.

Request a Free Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://datamintelligence.com/download-sample/geographic-atrophy-market?sz

Market opportunities and Growth Drivers:

The Increasing FDA Approval is Driving the Global Geographic Atrophy Market Growth

In August 2023, the FDA approved IZERVAY (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD), marking a significant advancement in treating this condition. According to a statement from Astellas Pharma Inc., IZERVAY is the first licensed GA medication that has shown a statistically significant reduction (p Less than 0.01) in the rate of GA progression, as demonstrated in two Phase 3 clinical trials, GATHER1 and GATHER2.

These pivotal trials assessed the safety and efficacy of monthly 2 mg intravitreal injections of IZERVAY in patients with GA secondary to AMD. The primary analysis over a 12-month period revealed that patients treated with IZERVAY experienced a significantly slower rate of GA progression compared to those who received a sham treatment. The findings from these trials provide strong support for IZERVAY's potential to slow the progression of GA, a condition that can lead to irreversible vision loss.

Geographic Atrophy Market Recent Development:

In February 2023, IVERIC bio, Inc. announced that the FDA had completed its review of the company's New Drug Application (NDA) for avacincaptad pegol (ACP), a novel complement C5 inhibitor being investigated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

In October 2022, NGM Biopharmaceuticals, Inc., a biotechnology company, reported the topline results of the CATALINA Phase 2 trial. This randomized, double-masked, sham-controlled trial evaluated the efficacy and safety of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

List of the Key Players in the Geographic Atrophy Market:

Apellis Pharmaceuticals, Inc. (US), Iveric Bio (US), Alkeus Pharmaceuticals, Inc. (US), Allegro Ophthalmics, LLC (US), Stealth BioTherapeutics (Cayman Islands), Gyroscope Therapeutics Limited (UK), Regenerative Patch Technologies, LLC (US), Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (US), and NGM Biopharmaceuticals Inc. (US) among others.

Research Process:

Both primary and secondary data sources have been used in the global Geographic Atrophy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/geographic-atrophy-market

Segment Covered in the Geographic Atrophy Market:

By Treatment Type: Medication (Pegcetacoplan), AREDS2 Supplements, Implantable Miniature Telescope (IMT).

By Age Group: Above 60 Years, Above 75 Years.

By End Users: Hospitals, Specialty Clinics, Others.

Regional Analysis for Geographic Atrophy Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

People Also Ask:

Most Frequently Asked Questions in the Geographic Atrophy Market Research Industry:

➠ What are the global figures for sales, production, consumption, imports, and exports in the Geographic Atrophy market?

➠ Who are the top manufacturers in the global Geographic Atrophy industry, and what is their current status in terms of production capacity, output, sales performance, pricing structure, cost analysis, profit margins, and overall revenue?

➠ What key opportunities are available for vendors in the Geographic Atrophy market, and what challenges are they likely to encounter?

➠ Which application areas, end-user segments, or product types are projected to experience significant growth, and how is the market share distributed among them?

➠ What are the major drivers and barriers influencing the growth trajectory of the Geographic Atrophy market?

➠ What are the primary sales, marketing, and distribution strategies used across the global Geographic Atrophy industry landscape?

Browse More Reports: https://www.datamintelligence.com/research-report/geographic-atrophy-market

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.